Adaptimmune Company

Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.
Technology: P4 Medicine
Industry: Genomic and Epigenominc Instabillity
Headquarters: United Kingdom
Founded Date: 2008
Employees Number: 51-100
Funding Status: IPO
Investors Number: 14
Total Funding: $249.5M
Estimated Revenue: Less than $1M
Last Funding Type: Post-IPO Equity

Visit Website
info@adaptimmune.com
@Adaptimmune
Register and Claim Ownership